Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Tyra Biosciences, Inc.NASDAQ: TYRA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $32.57M (cash outflow) rose 27.9% year over year, behind the +39.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 37.9% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +27.9% toward the trailing-twelve-month pace of +39.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (95.14M) USD
- Year-over-year change
- -36.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.14M) | -36.4% |
| FY2024 | 2024-12-31 | (69.77M) | -39.2% |
| FY2023 | 2023-12-31 | (50.14M) | +0.3% |
| FY2022 | 2022-12-31 | (50.29M) | -111.8% |
| FY2021 | 2021-12-31 | (23.75M) | — |
Operating Cash Flow vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 operating cash flow of $102.26M is the 6th largest of the 11 companies compared; the peer median is $99.14M.
- Its year-over-year change of +39.7% is the 2nd highest of 11, against a peer median of +6.5%.
- Over three fiscal years its annual growth of +23.7% compares with a peer median of +21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $178.64M | +18.9% | +11.5% | — | |
| LTM Mar 2026 | $150.95M | +31.1% | +29.3% | 304.4% | |
| LTM Mar 2026 | $134.47M | +12.4% | +54.4% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $116.24M | +31.7% | +49.3% | — |
| LTM Mar 2026 | $110.88M | -3.8% | +14.7% | — | |
| LTM Mar 2026 | $102.26M | +39.7% | +23.7% | — | |
| LTM Mar 2026 | $87.4M | -8.0% | — | 309.7% | |
| LTM Jun 2026 | $82.62M | -50.9% | +21.7% | 48.6% | |
| LTM Mar 2026 | $77.99M | -170.1% | -16.5% | 108.9% | |
| LTM Mar 2026 | $77.55M | +68.6% | +24.2% | 358.8% | |
| LTM Mar 2026 | $69.96M | +0.5% | -2.3% | 44.5% | |
| Peer median (excluding TYRA) | $99.14M | +6.5% | +21.7% | 206.6% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.89M | 10.59M | 13.53M | 22.8M | 28.01M |
| Change in Working Capital | (481K) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.49M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.97M) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Other Non-Cash Items | 3K | 3K | (1.25M) | (5.88M) | (2.12M) |
| Operating Cash Flow | (23.75M) | (50.29M) | (50.14M) | (69.77M) | (95.14M) |
| Capital Expenditures | (661K) | (559K) | (770K) | (664K) | (141K) |
| Acquisitions (Net) | 16K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (143.84M) | (263.62M) | (101.25M) |
| Sales of Investments | 0 | 0 | 0 | 165.89M | 173.86M |
| Other Investing Activities | 16 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (645K) | (559K) | (144.61M) | (98.4M) | 72.46M |
| Debt Repayment | (9K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 181.22M | 632K | 1.54M | 200M | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (420K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 514K | 0 | 0 | 2.56M | 0 |
| Financing Cash Flow | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Effect of Forex Changes | 0 | (757K) | 0 | 0 | 0 |
| Net Change in Cash | 286.96M | (50.97M) | (193.21M) | 33.96M | (14.58M) |
| Free Cash Flow | (24.41M) | (50.84M) | (50.91M) | (70.44M) | (95.28M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.